NewDel Biopharma Secures Global Exclusive Rights to Next-Generation Targeted Anti-Tumor Drug Through Technology Transfer Agreement with Jinan University
December 10, 2021, Shenzhen CityXinyue BiotechTechnology Co., Ltd. (hereinafter referred to as "Xinyue Bio") andJinan UniversitySigned the "Technology Transfer Agreement", with a total contract value exceedingRMB 300 millionIntroduction of Jinan UniversityProfessor Ding Ke's TeamDeveloped by Ding Ke, Lu Xiaoyun, and Zhang Zhang as the principal inventorsNew-Generation Targeted Anti-Tumor Drugs.Xinyue Biologics will obtain exclusive global rights to develop, manufacture, and commercialize the in-licensed drug, while the Dingke team will receive potential total proceeds exceeding RMB 300 million, including milestone payments and sales royalties.
This collaboration focuses on the field of precision oncology. The preclinical candidate drugs involved boast advantages such as novel structures, potent efficacy, wide safety margins, unique mechanisms of action, and well-defined biomarkers. Xinyue Biopharma will conduct further in-depth development based on clinical value and patient needs. The project is expected to enter clinical trials soon, aiming to promptly address the public’s health and life-saving needs.
Prof. Ding Kestated, “We are delighted to partner with Xinyue Biopharma, a company dedicated to innovative drug research and development in the Guangdong-Hong Kong-Macao Greater Bay Area. The collaborative project holds significant clinical value and promising development prospects. Through close cooperation between both parties, we aim to further accelerate the translation of our scientific achievements into clinical applications, thereby providing superior treatment options for cancer patients.”
He Xun, Chairman of NewYue Bio“The collaboration with Professor Ding Ke’s team is highly anticipated. This partnership marks a milestone in the development history of Xinyue Bio. Guided by clinical value, Xinyue Bio focuses on innovative drug development. By leveraging the robust innovation and R&D platform of Professor Ding Ke’s research group and integrating it with Xinyue Bio’s distinctive DEL3.0 technology platform, the synergy, complementarity, and joint exploration between the two platforms will further accelerate the effective translation of scientific achievements and expedite the progress of Xinyue Bio’s drug development pipeline, thereby working together to improve treatment outcomes for cancer patients in China and worldwide.”
Shenzhen Xinyue Biotechnology Co., Ltd. was established in April 2021 as the first biopharmaceutical company incubated by the Guangdong Provincial Small Molecule New Drug Innovation Center. Leveraging its independently owned intellectual property rights in DEL3.0 library construction and proprietary live-cell screening technologies, Xinyue Biotechnology has established a comprehensive lifecycle system for innovative drug design, R&D, and industrialization, targeting unmet clinical needs with a focus on first-in-class (FIC) therapeutics. The company is committed to becoming an internationally leading and distinctly specialized biopharmaceutical enterprise dedicated to novel drug discovery and development.
Professor Ding Ke, Professor at the School of Pharmacy, Jinan University; recipient of the National Science Fund for Distinguished Young Scholars; Chang Jiang Scholar Distinguished Professor appointed by the Ministry of Education; National Health and Family Planning Commission’s “Outstanding Young and Middle-Aged Expert”; Ministry of Science and Technology’s “Leading Talent in Scientific and Technological Innovation among Young and Middle-Aged Researchers”; and Leading Talent under the Organization Department of the CPC Central Committee’s “National Ten Thousand Talents Program.” Professor Ding Ke has been granted more than 30 invention patents, with multiple achievements transferred and commercialized. Notably, GZD824 (HQP1351), a drug for chronic myeloid leukemia (CML), has been approved for marketing in China for patients with chronic-phase or accelerated-phase CML harboring the T315I mutation. ASK120067, a third-generation inhibitor candidate for the treatment of non-small cell lung cancer (NSCLC), submitted its marketing application to the Center for Drug Evaluation (CDE) in November 2021.